VERFAHREN ZUR VERWENDUNG VON (1S,3S-)-3-AMINO-4-DIFLUORMETHYLENYL-1-CYCLOPENTAN-SÄURECPPMon, August 12th - 6:15 AM 2019
Harbour BioMed gets FDA nod to begin clinical trial for HBM4003 in cancerPharmaceutical Business ReviewMon, March 2nd - 7:14 PM 2020
Medexus expands its US product portfolio by acquiring hematology asset IXINITYPharmaceutical Business ReviewMon, March 2nd - 7:14 PM 2020
Pfizer, EMD Serono to scrap phase 3 study of avelumab in LA SCCHNPharmaceutical Business ReviewMon, March 16th - 8:09 PM 2020
BioStem Life Sciences announces expansion; contract manufacturing capabilities, and research and development laboratoryPharmaceutical Business ReviewMon, March 16th - 8:09 PM 2020
Pfizer’s abrocitinib meets co-primary efficacy endpoints in phase 3 AD trialPharmaceutical Business ReviewThu, March 19th - 8:12 PM 2020
Novartis receives Japanese approval for Zolgensma in spinal muscular atrophyPharmaceutical Business ReviewFri, March 20th - 8:10 PM 2020
Roche to begin Actemra/RoActemra trial with COVID-19 pneumonia patientsPharmaceutical Business ReviewFri, March 20th - 8:10 PM 2020
Feinstein Institutes begins three clinical trials for COVID-19 patientsPharmaceutical Business ReviewMon, March 23rd - 8:08 PM 2020
Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disordersPharmaceutical Business ReviewMon, March 23rd - 8:08 PM 2020

Pages